Novel peptide antagonists for modulating GPCR pharmacology

University of Oklahoma

Novel cardioprotective vasodilator peptides with enhanced affinity for AM and CGRP receptors have been developed.

This technology informs development of AM2/IMD-based pharmacological therapeutics with potential applications in diabetes, obesity, cardiovascular, cardiopulmonary, and renal diseases.

IP status: